mortality/aging
• mice being to die as early as 23 days after birth, with the majority of mice deceased by 8 weeks
• mice treated with the MEK inhibitor U0126 show increases in lifespan and survival
|
cardiovascular system
• aberrant cardiac morphology is seen at 12 weeks, with perturbed chamber arrangement and overall geometry
|
• atrial enlargement at 12 weeks
|
• ratio of heart weight-to-body weight is increased
|
• increase in left ventricular mass
• mice treated with U0126 show improved left ventricular mass and diastolic volumes
|
• ventricular enlargement at 12 weeks
|
• cardiac fibrosis is seen as early as 4 weeks and progressively increases with age
|
• mice begin showing overt signs of cardiac dysfunction in early adulthood
|
• fractional shortening is decreased after 12 weeks of age
• mice treated with the MEK inhibitor U0126 show improved fractional shortening
|
• mice exhibit obvious signs of heart failure, including anasarca, fluid retention, and listlessness
|
muscle
• fractional shortening is decreased after 12 weeks of age
• mice treated with the MEK inhibitor U0126 show improved fractional shortening
|
• overall architecture of the mitochondria is severely disrupted in hearts
|
• sarcomeres are out of register and normal pattern organization is disrupted in hearts
|
growth/size/body
• ratio of heart weight-to-body weight is increased
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
hypertrophic cardiomyopathy 4 | DOID:0110310 |
OMIM:115197 |
J:213370 |